Does Genotype Affect the Efficacy of PCSK9 Inhibitors in the Treatment of Familial Hypercholesterolemia?

Area of Science:

• Cardiovascular Medicine
• Genetics
• Pharmacology

Background:

• Familial hypercholesterolemia (FH) is a genetic disorder characterized by high LDL-C levels.
• PCSK9 inhibitors are effective in lowering LDL-C but their efficacy across different FH genotypes requires clarification.

Purpose of the Study:

• To review the impact of patient genotype on PCSK9 inhibitor efficacy in familial hypercholesterolemia.
• To explore how genotype-specific responses may influence clinical management strategies.

Main Methods:

• Systematic review of existing clinical evidence.
• Analysis of studies investigating PCSK9 inhibitor response in various FH genotypes.

Main Results:

• PCSK9 inhibitors demonstrate similar LDL-C-lowering effects across most FH genotypes.
• Efficacy exceptions noted in compound heterozygous and homozygous FH.
• Genotype is a less reliable predictor for LDL-C reduction compared to other external factors.

Conclusions:

• Genotype is not a primary determinant of PCSK9 inhibitor efficacy in FH, except in severe homozygous/compound heterozygous cases.
• Clinical management should consider factors beyond genotype for personalized treatment.
• Further research is needed to confirm if similar LDL-C reduction translates to comparable cardiovascular risk reduction across genotypes.